Pfizer $14 billion acquisition of Medivation

22/8/2016
Public acquisition

$ 14 billion

Completed

22/8/2016


Overview:

  • Pfizer has acquired cancer drug pharmaceutical company Medivation in a $14 billion deal.
  • Medivation is known especially for its new prostate cancer drug Xtandi.
  • The deal comes shortly after Medivation rejected a smaller offer by Sanofi, and only a few months after Pfizer's $5.2 billion purchase of Anacor.
  • Ropes & Gray (Christopher Comeau, Paul Kinsella) advised Pfizer.
  • Wachtell Lipton Rosen & Katz (Daniel Neff, Trevor Norwitz, Mark Gordon, Gregory Ostling, Ronald Chen) and Cooley (Jamie Leigh, Kenn Guernsey) advised Medivation.
  • Davis Polk & Wardwell (Alan Denenberg) represented Medivation financial adviser JPMorgan Securities.

Kurt Stumpo - Journalist - North America and the Carribean

Continue reading...

New to IFLR1000?

Register today for FREE:

  • Understand market dynamics, with data broken by deal type and more
  • Access law firms and lawyers involved in deals
  • Gain unique insight into lawyers recent work
REGISTER NOW

Sign in